Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovus Pharmaceuticals Inc. (INNV) Message Board

As one of the most avid posters on this board and

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 405
Posted On: 11/11/2016 12:25:04 AM
Posted By: Honeycomb777
As one of the most avid posters on this board and shareholder of the company, I would like to point out several key items that are CLEAR & FACTUAL after listening to the cc twice:

- 42% month over month growth rate from the Beyond Human Platform
- 3.1M YTD Revenue (only Q4 left to go)
- Multiple products selling well, especially Vesele and the Testosterone Booster.
- Vesele is selling 300 units PER DAY
- Will not do a reverse split just to uplist. Shareprice and timing have got to be right and then an uplist will happen as it is still a goal
- Confident that Fluticare will be approved by end of THIS year and bring in 10-15M in addition to the restated 2017 guidance of 15M...yes, that is potentially $30M folks.
- Clear that they will introduce new products as BH platform is working very well and touching millions. Sounds like even before Fluticare would launch (Q2 if approval hits by end of 2016) they would have complimentary products launched along with it to enhance this portion/segment of their product portfolio.
- Pre-paid expenses were on the high side because they want to ensure enough supply and mitigate any delays/disruptions, especially with the 3 highest-demand products. Some of this add'l supply will come months down the road and well into Q4, which is good that it got charged in Q3.
- Continue to enhance sales and partnerships outside of the US
- Margins are just simply incredible as the platform allows for more profit
- Restated at least 3 times that they are on track to finish 2016 with at least 5M - which would equate to a 1.9M Q4 but Damaj said that month over month has seen a 42% growth rate DO THE MATH ON THAT ONE ! 2017 at 15m plus another 10-15M once Fluticare is approved.


** Folks if this is still in the 20's tomorrow and going forward - I will buy this every hour on the hour because this time next year we are looking at a $28-30M revenue company IMO. I give that a better than 75% chance with 15M in the bag. Min price target for me is 80 cents and with Fluticare approval, should easily double overnight. Keep getting the word out there about the products as it is working !!


(1)
(0)




Innovus Pharmaceuticals Inc. (INNV) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us